地屈孕酮片辅助化疗对改善子宫内膜癌肿瘤标志物水平及炎症反应的应用研究

Application of Didroprogesterone Tablets as Adjuvant Chemotherapy in the Improvement of Tumor Markers and Inflammatory Reaction of Endometrial Carcinoma

目的:观察地屈孕酮片辅助化疗对子宫内膜癌患者血清肿瘤标志物水平及炎症反应的影响。方法:回顾性分析2018年1月—2021年10月焦作市妇幼保健院收治的80例子宫内膜癌患者临床资料,采用抽签法将其均分为两组,将单独实施化疗的40例患者列为对照组,将采用地屈孕酮片辅助化疗的40例患者列为观察组,比较两组患者治疗前后的血清肿瘤标志物水平、炎症指标及病灶缓解率,对所有患者开展为期1年的随访,比较两组患者生活质量及不良事件发生情况。结果:治疗后,观察组患者的癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、人附睾蛋白4(HE4)低于对照组,差异有统计学意义(t=2.520、2.786、2.140,P<0.05);治疗后,白细胞计数(WBC)、中性粒细胞(NE)、C-反应蛋白(CRP)水平低于对照组,差异有统计学意义(t=3.147、2.523、2.667,P<0.05);观察组的患者病灶总缓解率高于对照组,差异有统计学意义(χ^(2)=5.643,P<0.05);观察组患者QLICP-EN各维度评分均高于对照组,差异有统计学意义(t=2.216、2.827、2.629、2.394,P<0.05);观察组患者的不良事件发生率低于对照组,差异有统计学意义(χ^(2)=5.741,P<0.05)。结论:采用地屈孕酮片辅助子宫内膜癌化疗可有效控制患者的肿瘤标志物水平并缓解炎症反应,对促进其病灶改善、提升生活质量并降低不良事件发生风险均有积极意义。

Objective:To observe the effect of didroxyprogesterone tablets on serum tumor markers and inflammatory reaction in patients with endometrial cancer.Methods:Through taking 80 patients with endometrial cancer treated in the hospital from January 2018 to October 2021 as the research object,they were divided into two groups by drawing lots,and listed 40 patients who received chemotherapy alone as the control group,and 40 patients who received adjuvant chemotherapy with didroxyprogesterone tablets as the observation group.The serum tumor marker levels,inflammatory indicators and focal remission rates of the two groups before and after treatment were compared,and all patients were followed-up for one year.The quality of life and the occurrence of adverse events of the two groups were compared.Results:After treatment,CEA,CA19-9,and HE4in the observation group were lower than those in the control group(t=2.520,2.786,2.140;P<0.05).WBC,NE,and CRP levels were lower than those in the control group(t=3.147,2.523,2.667;P<0.05).The focal remission rate was higher than the control group(χ^(2)=5.643,P<0.05).During the follow-up period,the QLICP-EN scores of the observation group were higher than those of the control group(t=2.216,2.827,2.629,2.394;P<0.05).The incidence of adverse events were lower than the control group(χ^(2)=5.741,P<0.05).Conclusion:The use of didrogesterone tablets in adjuvant chemotherapy for endometrial cancer can effectively control the level of tumor markers and alleviate inflammatory reaction,which is of positive significance in promoting the improvement of its lesions,improving the quality of life and reducing the risk of adverse events.